Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade-Reference-Cited by-同舟云学术

Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade

Published:2019-08-01 Issue:8 Volume:5 Page:1195
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Lu Steve¹,Stein Julie E.¹,Rimm David L.²,Wang Daphne W.¹,Bell J. Michael¹,Johnson Douglas B.³,Sosman Jeffrey A.⁴,Schalper Kurt A.²,Anders Robert A.⁵,Wang Hao⁶,Hoyt Clifford⁷,Pardoll Drew M.⁸⁹,Danilova Ludmila⁶⁹,Taube Janis M.¹⁵⁸⁹

Affiliation:

1. Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, Maryland

2. Department of Pathology, Yale University School of Medicine, New Haven, Connecticut

3. Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

4. Department of Medicine, Division of Hematology-Oncology, Northwestern University Medical Center, and Robert H. Lurie Cancer Center, Chicago, Illinois

5. Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, Maryland

6. Division of Biostatistics & Bioinformatics at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medical Institutions, Baltimore, Maryland

7. Akoya Biosciences, Hopkinton, Massachusetts

8. Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, Maryland

9. Bloomberg~Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medical Institutions, Baltimore, Maryland

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Link

https://jamanetwork.com/journals/jamaoncology/article-pdf/5/8/1195/17773685/jamaoncology_lu_2019_oi_190040.pdf

Reference80 articles.

1. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.;Topalian;N Engl J Med,2012

2. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.;Taube;Clin Cancer Res,2014